Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare lab billing

This article was originally published in The Gray Sheet

Executive Summary

HCFA delays until Jan. 1, 2001 its requirement that independent laboratories bill hospitals, rather than HCFA, for the technical component of outpatient pathology services. Originally intended to take effect Aug. 1, the requirement forces labs to bill multiple payers for one service. Delay follows lobbying effort by the American Hospital Association, the College of American Pathologists, and the National Rural Health Association, who informed the agency in a June 29 letter that "too many adjustments are being required of hospital billing and computer systems at this time to allow them to absorb this additional change"

You may also be interested in...



Hospital, Pathology Lab Cost Burden Downplayed By GAO In TC Billing Review

CMS' annual recalibration of relative payment weights under PPS eventually would offset costs incurred by hospitals if labs were no longer able to bill directly to Medicare for certain pathology services, GAO finds

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel